SCHEMBL23294646

SCHEMBL23294646

COC(=O)c1[nH]nnc1-c1ccccc1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 4/20 0.38
▸ NR4A2 P43354 1/20 0.38
▸ ALPL P05186 1/20 0.38
▸ FGFR1 P11362 1/20 0.37
▸ FGFR2 P21802 1/20 0.37
▸ FGFR4 P22455 1/20 0.37
▸ FGFR3 P22607 1/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ STAT3 P40763 1/20 0.37
▸ HIF1A Q16665 1/20 0.37
▸ GABRA1 P14867 1/20 0.37
▸ GABRG2 P18507 1/20 0.37
▸ GABRB3 P28472 1/20 0.37
▸ GABRA5 P31644 1/20 0.37
▸ GABRA3 P34903 1/20 0.37
▸ ALDH1A1 P00352 6/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ ALPG P10696 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26849394 0.83 GAA (0.40) GAAKDM4EALDH1A1NPC1RAB9A
SCHEMBL23294571 0.83 HAO1 (0.41) GAAALPLKDM4EALDH1A1NPC1
SCHEMBL19669150 0.80 ALDH1A1 (0.53) GAAGABRA1GABRG2GABRB3GABRA5
SCHEMBL29244334 0.73 GAA (0.44) GAAKDM4EALDH1A1NPC1CYP1A2
SCHEMBL5601860 0.72 GAA (0.47) GAAKDM4EALDH1A1NPC1RAB9A
SCHEMBL19715740 0.72 RAB9A (0.48) ALPLKDM4EALDH1A1NPC1CYP1A2
SCHEMBL28327759 0.71 GAA (0.46) GAAKDM4EALDH1A1NPC1RAB9A
SCHEMBL9949375 0.70 MAPT (0.59) GAAALPLKDM4EALDH1A1NPC1
SCHEMBL9587880 0.70 KDM4C (0.44) GAAALPLALDH1A1NPC1RAB9A
SCHEMBL17263271 0.70 L3MBTL1 (0.45) FGFR1FGFR2FGFR4FGFR3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4051667-B1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS LILAC THERAPEUTICS INC (US) 2026-01-28 — — EP disclosed
CN-114929676-B Heterocyclic carboxylate compounds as glycolate oxidase inhibitors 紫丁香疗法有限公司 2025-04-29 — — CN disclosed
US-20250064787-A1 Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors LILAC THERAPEUTICS INC (US) 2025-02-27 — — US disclosed
US-12168002-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2024-12-17 — — US disclosed
EP-4470538-A2 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS Lilac Therapeutics, Inc. (US) 2024-12-04 — — EP disclosed
US-20240091200-A1 Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors Lilac Therapeutics, Inc. 2024-03-21 — — US disclosed
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2023-11-07 — — US disclosed
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2023-11-07 — — US disclosed
EP-4051667-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS Lilac Therapeutics, Inc. (US) 2022-09-07 — — EP disclosed
CN-114929676-A Heterocyclic carboxylate compounds as glycolate oxidase inhibitors 紫丁香疗法有限公司 2022-08-19 — — CN disclosed
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS Lilac Therapeutics, Inc. 2021-05-06 — — US disclosed
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS Lilac Therapeutics, Inc. 2021-05-06 — — US disclosed
WO-2021086874-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS GyanRx Sciences, Inc. (US) 2021-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240091200-A1 Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors UGDH, PGD, PNPO GAA 28/4885NR4A2 4737/4885ALPL 1290/4885
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors UGDH, PGD, PNPO GAA 28/4885NR4A2 4737/4885ALPL 1290/4885
US-12168002-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors UGDH, PGD, PNPO GAA 28/4885NR4A2 4737/4885ALPL 1290/4885
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS UGDH, PGD, PNPO GAA 28/4885NR4A2 4737/4885ALPL 1290/4885
US-20250064787-A1 Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors GLS, DUOX1, HAO1 GAA 78/4885NR4A2 4797/4885ALPL 2290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback